Holen Sie sich die Stockscreener-App
8.04
0.39%
-0.01
Schlusskurs vom Vortag:
$8.05
Offen:
$8
24-Stunden-Volumen:
10,654
Relative Volume:
0.01
Marktkapitalisierung:
$798.35M
Einnahmen:
$84.28M
Nettoeinkommen (Verlust:
$-171.30M
KGV:
-4.6279
EPS:
-1.7373
Netto-Cashflow:
$-171.21M
1W Leistung:
-4.42%
1M Leistung:
-4.42%
6M Leistung:
-26.63%
1J Leistung:
-42.93%
1-Tages-Spanne:
$8.00
$8.04
1-Wochen-Bereich:
$7.974
$8.56
52-Wochen-Spanne:
$6.66
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Firmenname
Ars Pharmaceuticals Inc
Sektor
Branche
Telefon
858-771-9307
Adresse
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
8.04 | 799.34M | 84.28M | -171.30M | -171.21M | -1.7373 |
VRTX
Vertex Pharmaceuticals Inc
|
434.83 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.33 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
799.68 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.36 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.52 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Eingeleitet | Northland Capital | Outperform |
| 2025-11-04 | Fortgesetzt | Roth Capital | Buy |
| 2025-09-04 | Eingeleitet | Roth Capital | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-08-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Bestätigt | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | Raymond James | Outperform |
| 2024-03-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Eingeleitet | William Blair | Outperform |
| 2022-12-13 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
Rally Mode: Can ARS Pharmaceuticals Inc sustain earnings growth2026 Reactions & Community Trade Idea Sharing Platform - baoquankhu1.vn
SPRY Stock Price, Quote & Chart | ARS PHARMACEUTICALS INC (NASDAQ:SPRY) - ChartMill
Winners Losers: Whats ARS Pharmaceuticals Incs historical returnTrade Entry Summary & Proven Capital Preservation Tips - baoquankhu1.vn
Northland initiates ARS Pharmaceuticals stock with outperform rating By Investing.com - Investing.com Canada
Northland initiates ARS Pharmaceuticals stock with outperform rating - Investing.com
SPRY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Ars Pharmaceuticals Earnings Call Highlights Neffy’s Early Traction - TipRanks
[ARS] Phathom Pharmaceuticals, Inc. SEC Filing - Stock Titan
[ARS] ROCKET PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Aberdeen Group plc Purchases 459,027 Shares of ARS Pharmaceuticals, Inc. $SPRY - marketbeat.com
Update Recap: Can ARS Pharmaceuticals Inc sustain earnings growth2026 Market WrapUp & Reliable Price Action Trade Plans - baoquankhu1.vn
Roth Capital Initiates Coverage of ARS Pharmaceuticals (SPRY) with Buy Recommendation - MSN
ARS Pharmaceuticals, Inc. (SPRY) reports Q4 loss, beats revenue estimates - MSN
[ARS] VERTEX PHARMACEUTICALS INC / MA SEC Filing - stocktitan.net
Profit Recap: Will ARS Pharmaceuticals Inc stock recover after earnings2026 Closing Moves & Weekly High Return Stock Opportunities - baoquankhu1.vn
ARS Pharma gains FDA clearance to remove age restriction from Neffy - MSN
Millennium-linked holders report 6.0% stake in ARS (NASDAQ: SPRY) - Stock Titan
Movement Recap: Can ARS Pharmaceuticals Inc sustain earnings growth2026 Opening Moves & Weekly High Return Opportunities - baoquankhu1.vn
Millennium Management LLC's Strategic Acquisition of ARS Pharmac - GuruFocus
Millennium Management LLC's Strategic Acquisition of ARS Pharmaceuticals Inc Shares - GuruFocus
FDA Removes Age Restriction for neffy 1 mg, Expanding Access to Needle-Free Epinephrine - Pharmacy Times
William Blair reiterates Outperform on ARS Pharma stock after FDA label update - Investing.com UK
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label - The Manila Times
ARS Pharmaceuticals Receives FDA Approval to Remove Age - GlobeNewswire
Age Requirement Removed for Neffy 1mg Dose in Anaphylaxis Treatment - Medical Professionals Reference
ARS Pharma rises after Japan nod for neffy nasal spray for allergy - MSN
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 8%Should You Buy? - MarketBeat
Asthma Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma - Barchart.com
Asthma Market: High-Growth Opportunities for Investors to 2034 - openPR.com
ARS Pharma secures $250M loan to accelerate Neffy rollout - MSN
Millennium Managers Hold 5.4% of ARS Pharmaceuticals (NASDAQ: SPRY) - Stock Titan
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.7%Time to Sell? - MarketBeat
(SPRY) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Will ARS Pharmaceuticals Inc stock recover after earnings2026 Buyback Activity & Real-Time Buy Zone Alerts - baoquankhu1.vn
Update Report: Can ARS Pharmaceuticals Inc sustain earnings growthBond Market & Community Verified Trade Signals - baoquankhu1.vn
Lexicon Pharmaceuticals (LXRX) 2025 10-K: pipeline updates, collaborations - Stock Titan
Bamco Inc. NY Boosts Stake in ARS Pharmaceuticals - National Today
Bamco Inc. NY Buys 1,228,532 Shares of ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Casdin Capital LLC Purchases New Stake in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
SPRY SEC FilingsARS Pharms 10-K, 10-Q, 8-K Forms - Stock Titan
Breakout Move: Can ARS Pharmaceuticals Inc stock outperform in a bear market2026 Update & Real-Time Price Movement Reports - baoquankhu1.vn
Institution Moves: What analysts say about ARS Pharmaceuticals Inc stock2026 Major Catalysts & Technical Pattern Recognition Alerts - baoquankhu1.vn
Guidance Update: Is ARS Pharmaceuticals Inc a top pick in the sectorProfit Target & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
[ARS] Tonix Pharmaceuticals Holding Corp. SEC Filing - Stock Titan
[ARS] CUMBERLAND PHARMACEUTICALS INC SEC Filing - Stock Titan
How (SPRY) Movements Inform Risk Allocation Models - Stock Traders Daily
ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines (SPRY) - Seeking Alpha
SPRY: Expanding neffy access, advancing urticaria trials, and strong global uptake drive future growth - TradingView
Finanzdaten der Ars Pharmaceuticals Inc-Aktie (SPRY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):